Neuraltus Pharmaceuticals completed a $17 million series A financing round with Latterell Venture Partners, VantagePoint Venture Partners, and Adam Street Partners. Each venture firm will have a seat on Neuraltus' board of directors.
The funding is expected to cover the costs of Phase I and II testing for Neuraltus' ALS therapy, a treatment to reduce dyskinesia in Parkinson's patients, and a drug therapy for Gaucher's disease.
"Neuraltus offers a strong pipeline of compounds for the treatment of serious neurological diseases for which there are few if any clinical options," says James Woody, Ph. D. of Latterell Venture Partners.